药物涂层球囊在真实世界股腘动脉队列中三年持续临床疗效
IN.PACT Global 研究为前瞻性、多中心、单臂研究,纳入 1406 例复杂股腘动脉病变患者,使用 IN.PACT Admiral 药物涂层球囊治疗。36 个月免于临床驱动的靶病变血运重建率为 76.9%,复合安全终点达成率 75.6%,全因死亡率 11.6%,大截肢率 1.0%。
要点
- 真实世界复杂股腘动脉病变中,DCB 术后 36 个月免于 CD-TLR 为 76.9%。
- CLTI 患者 36 个月免于 CD-TLR 显著低于间歇性跛行患者(67.6% vs 78.0%)。
- SFA 与腘动脉同时受累者 36 个月免于 CD-TLR 低于孤立 SFA 或腘动脉病变。
核心结论
- IN.PACT Admiral 药物涂层球囊治疗真实世界复杂股腘动脉病变,3 年随访显示持续临床疗效和低再干预率。
研究设计与样本
- 前瞻性、多中心、单臂 IN.PACT Global 研究(NCT01609296),64 个国际中心纳入 1535 例复杂病变患者,预设全临床队列 1406 例,平均年龄 68.6 岁,67.8% 为男性。
主要发现
- 36 个月免于临床驱动的靶病变血运重建(CD-TLR)的 Kaplan-Meier 估计值为 76.9%。
- 复合安全终点在 75.6% 的患者中达成。
- 36 个月全因死亡率为 11.6%,大截肢率为 1.0%。
- CLTI 患者 36 个月免于 CD-TLR 为 67.6%,显著低于跛行患者的 78.0%(p=0.003)。
- SFA 和腘动脉同时受累病变 36 个月免于 CD-TLR 为 69.2%,低于孤立 SFA 病变的 79.7% 或孤立腘动脉病变的 76.5%(log-rank p<0.001)。
关键数值与推荐
- 平均病变长度 12.09±9.54 cm;18.0% 为支架内再狭窄,35.5% 为完全闭塞,68.7% 有钙化。
- 36 个月 CD-TLR 预测因素包括病变长度增加、参考血管直径 ≤4.5 mm、支架内再狭窄、双侧病变、CLTI 和高脂血症。
临床怎么用
- 对于复杂股腘动脉病变,包括长病变、钙化、闭塞和支架内再狭窄,IN.PACT Admiral DCB 可提供持续的 3 年临床获益。
- CLTI 患者及 SFA 合并腘动脉病变患者 3 年再干预风险较高,应加强随访和预期管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: To report the 36-month outcomes from the prospective, multicenter, single-arm IN.PACT Global Study (ClinicalTrials.gov identifier NCT01609296) evaluating the performance of the IN.PACT Admiral drug-coated balloon (DCB) in real-world patients with femoropopliteal occlusive disease. Materials and Methods: The IN.PACT Global Study was conducted at 64 international sites and enrolled 1535 patients with complex lesions, which included bilateral disease, multiple lesions, de novo in-stent restenosis, long lesions, and chronic total occlusions. The predefined full clinical cohort included 1406 patients (mean age 68.6 years; 67.8% men) with claudication or rest pain treated with the study DCB. Mean lesion length was 12.09±9.54 cm; 18.0% had in-stent restenosis, 35.5% were totally occluded, and 68.7% were calcified. Freedom from clinically-driven target lesion revascularization (CD-TLR) was evaluated through 36 months. The safety composite endpoint was freedom from device- and procedure-related death through 30 days and freedom from major target limb amputation and clinically-driven target vessel revascularization within 36 months. All safety and revascularization events were reviewed by an independent clinical events committee. Results: The Kaplan-Meier estimate of freedom from CD-TLR through 36 months was 76.9%. The composite safety endpoint was achieved in 75.6% of patients. The 36-month all-cause mortality rate was 11.6%, and the major target limb amputation rate was 1.0%. The Kaplan-Meier estimate of freedom from CD-TLR through 36 months was significantly lower in patients with chronic limb-threatening ischemia (CLTI) compared with claudicants (67.6% vs 78.0%; p=0.003). Lesions affecting both the superficial femoral artery (SFA) and popliteal artery had lower Kaplan-Meier freedom from CD-TLR through 36 months (69.2%) than either isolated SFA (79.7%) or popliteal artery lesions (76.5%; log- rank p<0.001). Predictors of CD-TLR through 36 months included increased lesion length, reference vessel diameter ≤4.5 mm, in-stent restenosis, bilateral disease, CLTI, and hyperlipidemia. Conclusion: DCB angioplasty with the IN.PACT Admiral DCB for femoropopliteal disease in a diverse and complex real-world population is associated with sustained clinical efficacy and low rates of reinterventions at 3 years after the initial procedure.
引用
- Torsello G, Stavroulakis K, Brodmann M, et al. Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort. J Endovasc Ther. 2020. PMID: 32583749. doi:10.1177/1526602820931477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。